Business
Waters Products and Markets High-Performance and Ultra-Performance Liquid Chromatography HPLC is a standard technique used to identify and analyze the constituent components of a variety of chemicals and other materials.
WATERS CORP /DE/: Revenue grew 7% to $3.165B from $2.958B. Net income grew 0.8% to $643M from $638M. Free cash flow declined 12.9% to $540M from $620M. Operating margin contracted 257 bps to 25.36%. WATERS CORP /DE/'s annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue; inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 7% to $3.165B from $2.958BOK
- Profitability — Net income grew 0.8% to $643M from $638MOK
- Cash flow — Free cash flow declined 12.9% to $540M from $620MWatch
- Margins — Operating margin contracted 257 bps to 25.36%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 2 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as WATERS CORP /DE/ reports it. History and quarterly detail are in the app.
- Product$2.0B
- Instrument Systems$1.3B
- Service$1.2B
- Waters Instrument Systems$1.1B
- Waters Service$1.1B
Latest filings
- 8-K · Company announcement2026-08-21
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about WATERS CORP /DE/, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.